US measles surge blamed on vaccine fears

25 May 2008

A former Deputy Commissioner at the US Food and Drug Administration, Scott Gottleib, has criticized the "growing - but groundless fears - over the safety of traditional vaccines" by many parents for an outbreak of measles in the USA. Dr Gottleib, now a resident fellow at the American Enterprise Institute, a free-market-oriented think-tank, also accused New York state legislators of being "eager to help the disease prosper."

At the heart of the issue are concerns over the combination measles, mumps and rubella vaccine, which was the focus of claims that the product was linked to a rise in autism (Marketletters passim). Dr Gottleib points to what he termed the "political hysteria" which arose from speculation linking thimerosal, a mercury-containing preservative used in some vaccines, with autism.

The Centers for Disease Control and Prevention (CDC) has reported that, so far in 2008, there have been 64 new cases of measles, the highest rate since 2001. More than one third of these (22) were located in Brooklyn, New York.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight